oncology drug spending

Robust multiple myeloma treatment program holds promiseThe Medical College of Wisconsin’s multiple myeloma program is robust and growing.
Rapid oncology innovation raises management challenges for payersOncology is a complex and rapidly-evolving management challenge for payers.
Four things health execs should know about the oncology pipeline
Four things health execs should know about the oncology pipelineHere’s how you can recognize changes in the oncology pipeline and maximize value related to cancer care.
Are oncology pathways effective? AMCP presenters weigh inFaced with a proliferation of oncology treatments, payers have started using oncology pathways. But what do these programs look like, and are they really working?
Researchers discuss ‘less is more’ cancer treatment approachMost patients hear the word “carcinoma” or “cancer” and believe they may die if they do not seek treatment. But ASCO researchers say that may be a problematic mentality.
Biosimilars uptake may lag for cancer patients, physiciansBiosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting?
Weighing value in HER2+ breast cancer treatmentTargeted treatments of HER2-positive breast cancers have dramatically prolonged many patients’ lives. But treatment outcomes in clinical trial settings don’t always translate into comparable real-world clinical value.
Top 5 facts about cancer drug costsThe global oncology market was worth $107 billion in 2015, and global annual cancer drug costs surged by 11.5% from 2011 to 2015, according to a new report.